Caris Life Sciences announced that the Providence Swedish Cancer Institute and its Paul G. Allen Research Center have joined its Precision Oncology Alliance, bringing the network to 99 cancer centers, including 45 National Cancer Institute‑designated institutions, as of December 19 2025.
The addition expands Caris’s clinical footprint and provides access to a large, diverse patient population for its comprehensive genomic profiling services. By incorporating Providence Swedish’s patient samples and clinical outcomes, Caris enriches its multimodal database, which underpins the company’s AI‑driven insights and therapeutic recommendations across oncology care.
James Hamrick, MD, MPH, Chairman of the Caris POA, said the partnership “strengthens our shared commitment to accelerate precision oncology and deliver better options and outcomes for patients.” Ashwani ‘Ash’ Rajput, MD, Executive Medical Director of the Providence Swedish Cancer Institute, added that the alliance “deepens our collaborative, patient‑centered innovation and expands access to cutting‑edge data for both institutions.”
Caris’s Q3 2025 results—revenue up 113.4% YoY to $216.8 million and gross margin at 68.0%—demonstrate the company’s ability to scale its AI platform while maintaining strong profitability. The alliance expansion builds on that momentum, positioning Caris to capture additional high‑quality data that will accelerate its AI model training and support future drug‑development collaborations, such as the recent multi‑year partnership with Genentech that could unlock up to $1.1 billion in milestone payments.
In the competitive precision‑oncology landscape, Caris’s growing network of 99 centers gives it a broader data footprint than many peers, enhancing its ability to identify novel biomarkers and therapeutic targets. The alliance also strengthens Caris’s value proposition to biopharmaceutical partners seeking data‑driven drug discovery, reinforcing its strategy of building a global precision‑oncology ecosystem.
The partnership signals Caris’s continued focus on data‑centric growth and AI innovation, reinforcing its market position and providing a foundation for future clinical and commercial opportunities in oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.